Emory at Super Bowl LIX
Emory University has long been at the forefront of brain health innovation, sports medicine advancements, foundational scientific discovery, and translational drug development. From the lab to the field, Emory drives real-world solutions impacting athletes, families, and communities.
Emory is driving important discoveries in service to humanity in real time, through groundbreaking treatments with global leaders in drug discovery and research. Leading researchers include Emory College chemistry professor Dennis Liotta, a renowned leader in drug development, and School of Medicine assistant professor Christina Gavegnano, who has developed several novel, successful treatments while also championing undergraduate student research.
Revolutionizing Sports Medicine: Emory’s Leadership in Innovation and Impact
Key Individuals & Their Roles
Barbara Krauthamer, PhD
A driving force behind student engagement through micro-internships and professional development programs.
“The ability to connect academic discovery with practical application is a hallmark of Emory’s mission. Our students are actively contributing to advancements in sports medicine and brain health.”
Dennis Liotta, PhD
A global leader in drug discovery and development, a successful entrepreneur, and a visionary leader. Most notably, he is the co-inventor of two of the most important HIV drugs, emtricitabine and lamivudine, which are used by more than 90% of HIV-infected patients. He has also pioneered new approaches to drug development in academia, including co-founding Drug Innovation Ventures at Emory (DRIVE) and the Center for New Medicines. While Dr. Liotta’s biggest impact has come from the HIV/AIDS therapeutics he developed, he has also made important contributions to other therapeutic areas, such as neurological diseases and oncology, creating many clinical therapeutic agents to improve human health. He actively collaborates with many renowned researchers, including Dr. Gavegnano, on developing innovative solutions for brain health and other medical challenges.
Christina Gavegnano, PhD
A renowned researcher with a groundbreaking record, including one of the fastest FDA drug approvals in history. Christina’s work focuses on tackling inflammation, with applications in brain health, sports-related injuries, and infectious diseases. Christina collaborates with Dr. Liotta on the design, synthesis, and evaluation of brain-penetrant JAK2 inhibitors.
Callie Wigington, PhD
Program Director for the Center for New Medicines. The center is an integrated, one-stop hub for translating Emory's discoveries into the next generation of life-saving therapeutics. It provides the dedicated effort, innovative technology and infrastructure, and programmatic support needed to mobilize and enable discovery scientists toward therapeutic innovation, thus enhancing their likelihood of success and increasing Emory's impact in drug discovery and development.
Undergraduate Student Representatives
Lally Levin 27C
Chemistry & Economics Major
Undergraduate Researcher, Liotta Research Group
